Skip to main content

Enzo Biochem's Q3 Revenues Rise 3 Percent

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market Wednesday that its third-quarter revenues increased 3 percent with slight gains for both its life sciences and clinical lab businesses.

The New York-based firm brought in total revenues of $23.8 million for the three-month period ended April 30, compared with $23.1 million for the third quarter of 2009. Its life sciences business contributed $13 million of that revenues, up from $12.4 million year over year. Its clinical lab business had revenues of $10.8 million versus $10.6 million.

Enzo said that the revenue increase for its life science business was due to "a shift from contract revenue to higher-margin products," as well as contributions from Assay Designs, the research kits and reagents maker that the firm purchased in March 2009 for around $12.2 million.

Enzo posted a net loss of $4.6 million, or $.12 per share, compared to a net loss of $4.2 million, or $.11 per share, for Q3 2009.

The firm said that its operating expenses, including SG&A and legal costs, increased 27 percent to 44.8 million. It did not disclose its R&D spending.

Enzo Biochem finished the quarter with $34.4 million in cash, cash equivalents, and short-term investments.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.